Robert W. Baird upgraded shares of Stryker Corporation (NYSE:SYK) from a neutral rating to an outperform rating in a report published on Thursday, MarketBeat Ratings reports. They currently have $173.00 price objective on the medical technology company’s stock, up from their prior price objective of $161.00.

Several other analysts also recently issued reports on SYK. Zacks Investment Research downgraded Stryker Corporation from a buy rating to a hold rating in a research note on Thursday, July 27th. Royal Bank Of Canada boosted their price target on Stryker Corporation from $140.00 to $155.00 and gave the company an outperform rating in a research note on Friday, July 28th. Oppenheimer Holdings, Inc. set a $148.00 price target on Stryker Corporation and gave the company a hold rating in a research note on Friday, July 28th. Stifel Nicolaus boosted their price target on Stryker Corporation from $151.00 to $158.00 and gave the company a buy rating in a research note on Friday, July 28th. Finally, Cowen and Company restated a buy rating and issued a $160.00 price target (up from $150.00) on shares of Stryker Corporation in a research note on Sunday, July 30th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the company. Stryker Corporation presently has a consensus rating of Hold and an average target price of $152.10.

Stryker Corporation (SYK) traded down $1.07 on Thursday, reaching $155.40. The company had a trading volume of 936,961 shares, compared to its average volume of 1,229,068. The company has a market cap of $58,156.58, a P/E ratio of 24.63, a PEG ratio of 2.45 and a beta of 0.79. Stryker Corporation has a twelve month low of $108.29 and a twelve month high of $160.62. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.37 and a quick ratio of 1.61.

Stryker Corporation (NYSE:SYK) last released its quarterly earnings results on Thursday, October 26th. The medical technology company reported $1.52 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.02. The business had revenue of $3.01 billion during the quarter, compared to the consensus estimate of $2.97 billion. Stryker Corporation had a return on equity of 24.11% and a net margin of 14.67%. The firm’s quarterly revenue was up 6.1% on a year-over-year basis. During the same period in the previous year, the company posted $1.39 EPS. sell-side analysts predict that Stryker Corporation will post 6.47 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/stryker-corporation-syk-upgraded-at-robert-w-baird/1714026.html.

In other Stryker Corporation news, insider Lonny J. Carpenter sold 5,000 shares of the company’s stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $155.34, for a total value of $776,700.00. Following the completion of the transaction, the insider now owns 83,207 shares of the company’s stock, valued at approximately $12,925,375.38. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 7.40% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. Acrospire Investment Management LLC acquired a new position in Stryker Corporation in the 2nd quarter worth about $111,000. Motco increased its holdings in Stryker Corporation by 50.7% in the 2nd quarter. Motco now owns 826 shares of the medical technology company’s stock worth $115,000 after purchasing an additional 278 shares in the last quarter. Bollard Group LLC increased its holdings in Stryker Corporation by 0.4% in the 2nd quarter. Bollard Group LLC now owns 832 shares of the medical technology company’s stock worth $115,000 after purchasing an additional 3 shares in the last quarter. San Francisco Sentry Investment Group CA increased its holdings in Stryker Corporation by 47.8% in the 3rd quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock worth $143,000 after purchasing an additional 325 shares in the last quarter. Finally, Bruderman Asset Management LLC acquired a new position in Stryker Corporation in the 2nd quarter worth about $150,000. 74.15% of the stock is owned by institutional investors and hedge funds.

About Stryker Corporation

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Analyst Recommendations for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.